Skip to Content
Visit ConferenceInsider to read about the AAO2016 cataract topics. Read more

Cromolyn (Ophthalmic)

Pronunciation

Pronunciation

(KROE moe lin)

Index Terms

  • Crolom
  • Cromoglicate
  • Cromoglycic Acid
  • Cromolyn Sodium
  • Disodium Cromoglycate
  • DSCG
  • Sodium Cromoglicate
  • Sodium Cromoglycate

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Ophthalmic, as sodium:

Generic: 4% (10 mL)

Pharmacologic Category

  • Mast Cell Stabilizer

Pharmacology

Mast cell stabilizer that inhibits the in vivo and in vivo release of histamine and slow-reacting substance of anaphylaxis (SRS-A) associated with antigen-mediated reactions.

Absorption

~0.03%

Onset of Action

Response to treatment: May be seen within a few days; treatment for up to 6 weeks is often required

Use: Labeled Indications

Conjunctivitis/keratitis: Treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis

Contraindications

Hypersensitivity to cromolyn or any component of the formulation

Dosing: Adult

Conjunctivitis and keratitis: Ophthalmic: Instill 1 to 2 drops in each eye 4 to 6 times daily at regular intervals. Continue therapy as long as needed; treatment for up to 6 weeks may be required.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Pediatric

Conjunctivitis and keratitis: Ophthalmic: Children ≥4 years and Adolescents: Refer to adult dosing.

Dosing: Renal Impairment

There are no dosage adjustments provided in the manufacturer’s labeling. However, dosage adjustment unlikely due to low systemic absorption.

Dosing: Hepatic Impairment

There are no dosage adjustments provided in the manufacturer’s labeling. However, dosage adjustment unlikely due to low systemic absorption.

Administration

For ophthalmic use only. Wash hands prior to use. Instill drops inside the lower eyelid; avoid instilling directly on the cornea. To avoid contamination, do not touch dropper tip to eye, eyelid, fingers, or any other surface. Do not wear contact lenses during treatment.

Storage

Store at 15°C to 25°C (59°F to 77°F). Protect from light. Store in original carton.

Drug Interactions

There are no known significant interactions.

Adverse Reactions

Frequency not defined.

Ocular: Conjunctival injection, dryness around the eye, edema, eye irritation, immediate hypersensitivity reactions, itchy eyes, puffy eyes, styes, rash, watery eyes

Respiratory: Dyspnea

Warnings/Precautions

Concerns related to adverse effects:

• Irritation: May cause transient burning or stinging upon instillation.

Special populations:

• Contact lens wearers: Some products may contain benzalkonium chloride which may be absorbed by contact lenses; do not wear contact lenses during treatment.

Other warnings/precautions:

• Appropriate use: For topical ophthalmic use only; not for injection. To avoid contamination, do not touch dropper tip to eye, eyelid, fingers, or any other surface when placing drops in eyes.

Pregnancy Risk Factor

B

Pregnancy Considerations

Adverse events have not been observed in animal reproduction studies.

Patient Education

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Patient may experience stinging or burning. Have patient report immediately to prescriber shortness of breath, vision changes, eye pain, severe eye irritation, or eye discharge (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.

Hide